Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 4Completed 2Withdrawn 1Unknown 1Terminated 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2966Carcinoma, Renal Cell 882Urinary Bladder Neoplasms 711Kidney Neoplasms 457Breast Neoplasms 408Neoplasms 390Neoplasm Metastasis 229Carcinoma, Non-Small-Cell Lung 229Lung Neoplasms 216Ovarian Neoplasms 211Colorectal Neoplasms 204Melanoma 195Carcinoma, Transitional Cell 190Testicular Neoplasms 171Pancreatic Neoplasms 142Sarcoma 129Head and Neck Neoplasms 121Colonic Neoplasms 120Wilms Tumor 119Uterine Cervical Neoplasms 116Stomach Neoplasms 98Neuroblastoma 90Multiple Myeloma 88Lymphoma, Non-Hodgkin 86Esophageal Neoplasms 86Lymphoma 83Carcinoma, Hepatocellular 81Carcinoma, Ovarian Epithelial 80Recurrence 75Squamous Cell Carcinoma of Head and Neck 74

Interventions

Erlotinib Hydrochloride 1Botulinum Toxins, Type A 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Hereditary leiomyomatosis and renal cell cancer × Genitourinary × Clear all
NCT01130519 2025-02-21

A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
83 enrolled 17 charts
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell, Kidney Neoplasms

NCT00971620 2017-04-07

Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
18 enrolled 22 charts
Genitourinary

Hereditary leiomyomatosis and renal cell cancer, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡